Tempest Therapeutics Says Justin Trojanowski To Resign As Principal Financial Officer Effective Sept 1; Nicholas Rossettos Appointed As CFO, Principal Financial Officer
-SEC Filing
Read original at benzingaStocks · News reference
On August 13, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the "Company"), entered into a purchase agreement (the "Purchase Agreement") and a registration rights agreement (the
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
-SEC Filing
Read original at benzingaFiled: 2026-08-24 AccNo: 0001193125-26-363695 Size: 177 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgar-SEC Filing
Read original at benzinga